![\"F.](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/d295bae68c32358ba6ac888e76c1cca2.png\")
F. Hoffmann-La Roche Ltd <\/p>\n F. Hoffmann-La Roche Ltd <\/p>\n
With this approval, Roche\u2019s automated mass spectrometry platform now offers the industry\u2019s broadest in vitro diagnostic menu with 39 tests, including tests for therapeutic drug monitoring for immunosuppressants and antibiotics, as well as steroid hormones and vitamin D metabolites.<\/p>\n
The comprehensive menu brings the sensitivity and specificity of gold-standard testing into routine labs for a wide range of the most frequently tested targets.<\/p>\n
The fully automated solution replaces labour-intensive manual workflows, reducing turnaround times and supporting faster, standardised, high-quality care.<\/p>\n
Basel, 11 December 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has secured CE Mark approval for its mass spectrometry reagent pack for antibiotics drug monitoring. This establishes Roche’s in-vitro diagnostics (IVD) menu as the broadest available for any automated mass spectrometry platform, including already 39 of the most frequently tested targets.<\/p>\n
\u201cWhen patients get results sooner, we increase the likelihood that they will get the right treatment,\u201d said Matt Sause, CEO of Roche Diagnostics. \u201cWith a comprehensive menu for automated mass spectrometry, we are giving clinicians and laboratories the tools to make faster, more precise diagnoses, reducing the time from sample to result. This approach also allows clinicians to better monitor the effectiveness of drug therapies and to optimise antibiotic use, a vital step in combating the major global healthcare challenge of antimicrobial resistance.”<\/p>\n
The cobas\u00ae Mass Spec solution Ionify\u00ae reagent portfolio includes tests for therapeutic drug monitoring for immunosuppressants and antibiotics, along with steroid hormones and vitamin D metabolites. These tests will enable laboratories to transition from labour-intensive and manual operation to a fully automated, standardised, easy to use solution.1-3 Roche remains committed to expanding this menu with additional assays in the coming years, including the first panel in drugs of abuse testing and further expanding the menu of therapeutic drug monitoring parameters.<\/p>\n
The cobas Mass Spec solution is currently available in selected markets accepting the CE mark, as well as other markets including the United Kingdom, Canada and Japan. In parallel, Roche achieved “moderate complexity” categorisation under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) of the first analyte in the US. As the first mass spectrometry assay to receive this designation, it marks a significant step toward broadening clinical utility across routine laboratories by eliminating the need for specialists to run the assay.\u00a0 Roche is continuously working with regulatory authorities around the world to further expand system and assay availability.<\/p>\n
Story Continues <\/p>\n
About the cobas Mass Spec solution
The high specificity, sensitivity and accuracy of mass spectrometry is considered the diagnostic \u2018gold standard\u2019 for various clinical situations, for example, measurements of steroid hormones in endocrinology, vitamin D testing, the monitoring of immunosuppressants and therapeutic drugs. The cobas Mass Spec solution combines the unmatched sensitivity and specificity of mass spectrometry with a fully automated, integrated, and standardised workflow, making this traditionally complex analytical method accessible to routine laboratories.<\/p>\n
As part of the trusted cobas ecosystem, the cobas Mass Spec solution can integrate seamlessly with Roche\u2019s clinical chemistry, immunochemistry, and laboratory IT systems, enabling laboratories to fully streamline workflows.<\/p>\n
In July 2025, the cobas Mass Spec solution was awarded the Best New Clinical Diagnostics Instrumentation of 2024 in the Scientists’ Choice Awards\u00ae 2025.\u00a0 The Awards were first introduced in 2007 by SelectScience, with nominations collected and assessed by their editors and the most popular nominations put to vote among their readership of scientists.<\/p>\n
For more information about the cobas Mass Spec, please visit diagnostics.roche.com\/MassSpec<\/a><\/p>\n About Roche For over 125 years, sustainability has been an integral part of Roche\u2019s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.<\/p>\n Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.<\/p>\n For more information, please visit www.roche.com<\/a>.<\/p>\n All trademarks used or mentioned in this release are protected by law.<\/p>\n References
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world\u2019s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.<\/p>\n
[1] Grebe SK, Singh RJ. LC-MS\/MS in the Clinical Laboratory – Where to From Here? Clin Biochem Rev. 2011;32(1):5-31.
[2] Hristova J & Svinarov D. Enhancing precision medicine through clinical mass spectrometry platform. Biotechnology & Biotechnological Equipment. 2022;36(1):107-117.
[3] Ketha SS, Singh RJ, Ketha H. Role of Mass Spectrometry in Clinical Endocrinology. Endocrinol Metab Clin North Am. 2017;46(3):593-613.<\/p>\n